Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Isabel Boned del Río"'
Autor:
Greg G. Jones, Isabel Boned del Río, Sibel Sari, Aysen Sekerim, Lucy C. Young, Nicole Hartig, Itziar Areso Zubiaur, Mona A. El-Bahrawy, Rob E. Hynds, Winnie Lei, Miriam Molina-Arcas, Julian Downward, Pablo Rodriguez-Viciana
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
Targeted inhibition of the ERK-MAPK pathway is challenged by the development of resistance and toxicity. Here, the authors show that SHOC2 genetic inhibition impairs lung tumour development and improves MEK inhibitor efficacy in RAS- and EGFR-mutant
Externí odkaz:
https://doaj.org/article/63c728d50eef448aa2fdb9117a059704
Autor:
Greg G. Jones, Sibel Sari, Pablo Rodriguez-Viciana, Nicole Hartig, Amandeep Bhamra, Ewa Rejnowicz, Isabel Boned del Río, Benjamin Ringham-Terry, Winnie Lei, Lucy C. Young, Silvia Surinova
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, vol 116, iss 27
Proceedings of the National Academy of Sciences of the United States of America, vol 116, iss 27
Significance The ERK signaling pathway is hyperactivated in a majority of cancers. However, because it mediates myriad physiological responses, the clinical efficacy of current ERK pathway inhibitors has been severely limited by toxicity. This study
Autor:
Sibel Sari, Nicole Hartig, Aysen Sekerim, Julian Downward, Itziar Areso Zubiaur, Miriam Molina-Arcas, Winnie Lei, Greg G. Jones, Isabel Boned del Río, Lucy C. Young, Mona El-Bahrawy, Pablo Rodriguez-Viciana, Robert E. Hynds
Publikováno v:
Nature Communications
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
Nature communications, vol 10, iss 1
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
Nature communications, vol 10, iss 1
Targeted inhibition of the ERK-MAPK pathway, upregulated in a majority of human cancers, has been hindered in the clinic by drug resistance and toxicity. The MRAS-SHOC2-PP1 (SHOC2 phosphatase) complex plays a key role in RAF-ERK pathway activation by
Autor:
Frank McCormick, Greg G. Jones, Joshua R. Wainwright, Lucy C. Young, Nicole Hartig, Benjamin Ringham-Terry, Sibel Sari, Isabel Boned del Río, Pablo Rodriguez-Viciana
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, vol 115, iss 45
Dephosphorylation of the inhibitory "S259" site on RAF kinases (S259 on CRAF, S365 on BRAF) plays a key role in RAF activation. The MRAS GTPase, a close relative of RAS oncoproteins, interacts with SHOC2 and protein phosphatase 1 (PP1) to form a hete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043fd74764d8eeaa7289fdbb429b878f
https://escholarship.org/uc/item/9ct3g7st
https://escholarship.org/uc/item/9ct3g7st
Autor:
Sibel Sari, Maria De Las Nieves Amalia Peltzer, Isabel Boned del Río, Pablo Rodriguez-Viciana, Sergio A. Quezada, York Posor, Greg G. Jones, Jake Y. Henry
Publikováno v:
Molecular Cancer Research. 18:A19-A19
The RAS-RAF-MEK-ERK signaling pathway plays an important role throughout mammalian development, from embryogenesis to tissue-specific cellular homeostasis, and its aberrant activation is a major driver of human cancer. Mouse models have highly improv
Autor:
Sibel Sari, Isabel Boned del Río, Julian Downward, Nicole Hartig, Mona El-Bahrawy, Aysen Sekerim, Pablo Rodriguez-Viciana, Miriam Molina-Arcas, Greg G. Jones, Lucy C. Young
Publikováno v:
Molecular Cancer Research. 18:B26-B26
Mutual exclusivity of RAS and BRAF mutations in multiple cancer types illustrates the key role of the RAF-MEK-ERK signaling pathway in mediating RAS oncogenesis. Although MEK inhibitors in particular are potent and specific, their on-target toxicity